Abbott Laboratories
Here’s whether Abbott Laboratories (ABT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 52 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.17% over 10 days); weak 1-year return of -35.4%; 3-month momentum negative (-19.8%). Currently 36.6% off its 52-week high. Score: -5/7.
ABT is trading below its 200-day MA ($114.49) — a key warning sign the longer-term trend is under pressure. An RSI of 52.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -35.4% compares to +22.9% for SPY (trailed the market by 58.2%). The current 36.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.